Abstract

CNIMDR‑1.0 is a complete, clinic‑grade, non‑invasive macular drug‑delivery system designed to replace intravitreal injections.

It integrates:

  • a soft peri‑ocular acoustic ring (SPAR‑1)

  • a hydrogel‑nanocarrier drug layer (HN‑DL)

  • multi‑modal acoustic transport physics

  • a gravity‑optimized treatment bed

  • a comfort‑first patient interface

  • closed‑loop safety monitoring

This architecture is fully open‑hardware and directly supported by several previously posted Caldwell inventions.

A lookup index is included at the end of this document so builders can reference the exact physics engines and testbeds that make CNIMDR‑1.0 viable.

1. PURPOSE

CNIMDR‑1.0 eliminates the need for intravitreal injections by delivering macular therapeutics through:

  • non‑invasive acoustic posterior transport

  • hydrogel‑nanocarrier migration through scleral pathways

  • gravity‑optimized ocular geometry

  • a soft, non‑contact peri‑ocular ring

  • a controlled 10–15 minute treatment session

This system is designed for:

  • AMD (wet/dry)

  • diabetic macular edema

  • future macular therapeutics

  • research labs testing non‑invasive ocular delivery

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Download

Share

COinS